Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2024 Mar 15

PMID 38488976

Authors

Xenofon Baraliakos

Annette E Szumski

Kenneth K Kwok

Bonnie Vlahos

Cecilia E Borlenghi

Affiliations

Soon will be listed here.

Abstract

Introduction: Short-term placebo (PBO)- or active-controlled clinical studies have demonstrated that etanercept (ETN) is effective and well tolerated in patients with radiographic axial spondyloarthritis (r-axSpA) with long-term efficacy and safety continuing for up to 7 years after treatment start. Short-term randomized controlled trials (RCTs) have shown the efficacy of ETN after 12-24 weeks, with statistically significant improvements as early as week 2. This post hoc analysis investigated the timeframe (i.e., temporal responses) in which patients with r-axSpA achieved their first clinical response with ETN and how patients responded over a longer period according to different temporal responses in index studies.

Methods: Data were analyzed from three phase 3/4 PBO- or sulfasalazine-controlled RCTs of ETN for the treatment of r-axSpA (index studies). Long-term open-label extension (OLE) studies assessed how patients responded over a longer period according to different temporal responses ("Early," "Intermediate," "Late," or "Non-response") in their corresponding index studies.

Results: Within each index study, patient responses differed significantly between ETN and control arms for achievement of Assessment in SpondyloArthritis international Society (ASAS) 20 and other measures of treatment response. In general, the proportion of responders in the OLE studies was high for those with "Early" and "Intermediate" responses as defined in the index studies. Despite patients being considered non-responders in the index studies, a large proportion achieved response on continued treatment in the OLE studies over the longer term, including through 48 weeks.

Conclusions: Response in the index studies was maintained in the long term, and continued treatment was warranted in a large proportion of patients despite initial non-response. Absence of an early response in index studies did not predict non-response over the long term, and early response to treatment was not always a predictor for later response.

Trial Registration: NCT00421915; NCT00247962; NCT00356356; NCT00421980; NCT00410046.

References

Taurog J, Chhabra A, Colbert R . Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med. 2016; 374(26):2563-74. DOI: 10.1056/NEJMra1406182. View

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X . ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022; 82(1):19-34. DOI: 10.1136/ard-2022-223296. View

Gorman J, Sack K, Davis Jr J . Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346(18):1349-56. DOI: 10.1056/NEJMoa012664. View

Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L . Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003; 48(6):1667-75. DOI: 10.1002/art.11017. View

Davis Jr J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D . Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48(11):3230-6. DOI: 10.1002/art.11325. View

Calin A, Dijkmans B, Emery P, Hakala M, Kalden J, Leirisalo-Repo M . Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004; 63(12):1594-600. PMC: 1754832. DOI: 10.1136/ard.2004.020875. View

van der Heijde D, Da Silva J, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X . Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006; 65(12):1572-7. PMC: 1798458. DOI: 10.1136/ard.2006.056747. View

Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P . Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011; 70(5):799-804. PMC: 3070274. DOI: 10.1136/ard.2010.139261. View

Braun J, van der Horst-Bruinsma I, Huang F, Burgos-Vargas R, Vlahos B, Koenig A . Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63(6):1543-51. DOI: 10.1002/art.30223. View

10.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J . Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013; 15(3):R67. PMC: 4060369. DOI: 10.1186/ar4244. View

11.

Nam E, Lee W . Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers. Medicine (Baltimore). 2020; 99(41):e22668. PMC: 7544430. DOI: 10.1097/MD.0000000000022668. View

12.

Arends S, Brouwer E, Efde M, van der Veer E, Bootsma H, Wink F . Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2016; 35(1):61-68. View

13.

Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B . Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012; 39(4):836-40. DOI: 10.3899/jrheum.110885. View

14.

Landewe R, van Tubergen A . Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015; 17(7):47. PMC: 4464370. DOI: 10.1007/s11926-015-0522-3. View

15.

Baraliakos X, Szumski A, Koenig A, Jones H . The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2018; 48(6):997-1004. DOI: 10.1016/j.semarthrit.2018.10.019. View

16.

Damjanov N, Al Shehhi W, Huang F, Kotak S, Burgos-Vargas R, Shirazy K . Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatol Int. 2016; 36(5):643-51. DOI: 10.1007/s00296-016-3452-0. View

17.

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P . Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2):582-91. DOI: 10.1002/art.20852. View

18.

van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54(7):2136-46. DOI: 10.1002/art.21913. View

19.

Barkham N, Keen H, Coates L, OConnor P, Hensor E, Fraser A . Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009; 60(4):946-54. DOI: 10.1002/art.24408. View

20.

Bao C, Huang F, Khan M, Fei K, Wu Z, Han C . Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford). 2014; 53(9):1654-63. DOI: 10.1093/rheumatology/keu132. View